ScreenerHero

NMRA Neumora Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · neumoratx.com
0.4683USD-0.57%Mkt Cap: 87.99M $P/E: —

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. Th…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap87.99M USD
Enterprise Value24.92M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-236.93M USD
Revenue/Share—
Last Price0.4683 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees63
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.70
PEG—
EV/EBITDA-0.12
EV/Revenue—
P/S—
P/B1.98
EPS (TTM)-1.23
EPS (Forward)-0.67
52W Range
0.45191% of range3.650
52W High3.650 USD
52W Low0.4519 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-228.10%
ROA-124.02%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-206.44M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-112.98%
Net Debt-63.58M USD
Net Debt/EBITDA0.31
Balance Sheet
Debt/Equity0.53
Current Ratio4.50
Quick Ratio4.21
Book Value/Sh0.24 USD
Cash/Share0.62 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)6.143 USD
Upside (mean)+1211.7%
Target Range3.000 USD – 14.00 USD
3.000+1211.7% to mean14.00
# Analysts7
Ownership
Shares Out.187.90M
Float116.36M
Insiders23.08%
Institutions60.13%
Short Interest
Short Ratio8.8d
Short % Float6.35%
Short % Out.3.71%
Shares Short6.98M
Short (prev mo.)7.99M
Technical
SMA 501.253 (-62.6%)
SMA 2001.920 (-75.6%)
Beta2.98
S&P 52W Chg16.45%
Avg Vol (30d)1.60M
Avg Vol (10d)2.41M
Technical Indicators
RSI (14)19.1
MACD-0.2308
MACD Signal-0.2251
MACD Hist.-0.0057
BB Upper1.246 USD
BB Middle0.7626 USD
BB Lower0.2794 USD
BB Width126.73%
ATR (14)0.0893 USD
Vol Ratio (20d)1.41x